[{"id":"d4373c8a-0565-4b22-8228-93e418e1dc46","acronym":"","url":"https://clinicaltrials.gov/study/NCT01068509","created_at":"2021-01-18T04:12:42.103Z","updated_at":"2024-07-02T16:37:22.593Z","phase":"Phase 2b","brief_title":"Ovarian Cancer Vaccine for Patients in Remission","source_id_and_acronym":"NCT01068509","lead_sponsor":"Prima BioMed Ltd","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cvac (cancer vaccine MUC-1)"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 07/01/2010","start_date":" 07/01/2010","primary_txt":" Primary completion: 08/01/2013","primary_completion_date":" 08/01/2013","study_txt":" Completion: 04/01/2015","study_completion_date":" 04/01/2015","last_update_posted":"2017-05-11"}]